Intra-Cellular Therapies Promotes Michael Halstead to President

Intra-Cellular Therapies, a biopharmaceutical company focused on developing therapeutics for central nervous system disorders, has announced several leadership changes and executive appointments. The company promoted Michael Halstead, J.D. to the position of President, where he will oversee various functions including legal, human resources, manufacturing, supply chain, quality, compliance, information technology, and external innovation. Halstead, who has been with the company since 2014, was previously serving as the Executive Vice President and General Counsel.

In addition to this, the company also announced that Senior Vice President and Chief Financial Officer, Larry Hineline, will be retiring after more than 20 years of service. Hineline, who has been the CFO since June 2002, will remain with the company through the transition as they initiate an external search for a new Chief Financial Officer.

Intra-Cellular Therapies has expressed gratitude for Hineline's significant contributions over the years, as the company evolved from a private entity to a fully integrated public biopharmaceutical company. Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, thanked him for his dedication and wished him all the best in his well-deserved retirement.

These executive appointments and leadership changes come at a crucial time as Intra-Cellular Therapies continues to build on its commercial success and advance its broad pipeline. The company is leveraging its intracellular approach, founded on Nobel prize-winning research, to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

Today the company's shares have moved -0.3% to a price of $65.2. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.